PEG-Intron Phase II combination data

Schering-Plough (SGP) presented results of an open label Phase II dose-ranging study of PEG-Intron with its Rebetol ribavirin nucleoside analog in

Read the full 210 word article

How to gain access

Continue reading with a
two-week free trial.